Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Starpharma has entered into a research and option agreement with Radiopharm Theranostics to develop a dendrimer-drug conjugate using Starpharma’s DEP® platform technology. This partnership marks Starpharma’s first radiopharmaceutical collaboration and signifies a significant milestone in their strategy to develop high-value assets and form strategic partnerships. The agreement allows Radiopharm an exclusive option to license the asset, with potential financial benefits for Starpharma, including upfront payments, success-based milestones, and royalties. This collaboration is expected to enhance Starpharma’s industry positioning by expanding their commercial options and opportunities for growth.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a company focused on developing innovative radiopharmaceuticals. They collaborate with partners to explore new mechanisms and modalities in the targeted radiotherapeutic sector, aiming to improve the efficacy and safety of radiopharmaceutical vectors.
Average Trading Volume: 3,947,480
Technical Sentiment Signal: Hold
Current Market Cap: A$68.58M
Learn more about RAD stock on TipRanks’ Stock Analysis page.